Fluctuation of systemic immunity in melanoma and implications for timing of therapy

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 958-975

  Leontovich, Alexey A ^a   Dronca, Roxana S ^a   Suman, Vera J ^a   Ashdown, Martin L ^b   Nevala, Wendy K ^a   Thompson, Michael A ^a   Robinson, Andrew ^b   Kottschade, Lisa A ^a   Kaur, Judith S ^a   McWilliams, Robert R ^a   Ivanov, Leonid V ^c   Croghan, Gary A ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GRINNELL COLLEGE   (United States)

Author keywords

Biorhythm; Cancer; Computer simulation; Cytokines; Dynamics; Immune Cells; Inflammation; Infradian; Oscillation

Indexed keywords

C REACTIVE PROTEIN; TEMOZOLOMIDE; CYTOKINE;

ADULT; AGED; ARTICLE; BIOLOGICAL RHYTHM; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OSCILLATION; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TIME TO TREATMENT; TUMOR IMMUNITY; BLOOD; IMMUNOLOGY; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84860857316     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e433     Document Type: Article

References (43)

1. E Linos, SM Swetter, MG Cockburn, GA Colditz, CA Clarke: Increasing burden of melanoma in the United States. J Invest Dermatol, 129:1666-74. (2009)
2. A Jemal, R Siegel, E Ward, Y Hao, J Xu, MJ Thun: Cancer statistics, CA Cancer J Clin, 59:225-49 (2009)
3. CM Balch, JE Gershenwald, SJ Soong, JF Thompson, MB Atkins, DR Byrd, AC Buzaid, AJ Cochran, DG Coit, S Ding, AM Eggermont, KT Flaherty, PA Gimotty, JM Kirkwood, KM McMasters, MC Mihm Jr, DL Morton, MI Ross, AJ Sober, VK Sondak: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol, 19:3635-48 (2001) (Pubitemid 32786276)
4. WK Nevala, CM Vachon, AA Leontovich, CG Scott, MA Thompson, SN Markovic: Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res,15:1931-1939 (2009)
5. J Weber: Immunotherapy for melanoma. Curr Opin Oncol (2010)
6. JM Kirkwood, AA Tarhini, MC Panelli, SJ Moschos, HM Zarour, LH Butterfield, HJ Gogas. Next generation of immunotherapy for melanoma.: J Clin Oncol, 26:3445-3455 (2008)
7. G Parmiani, C Castelli, M Santinami, L Rivoltini: Melanoma immunology: past, present and future. Curr Opin Oncol, 19:121-127 ( 2007) (Pubitemid 46204351)
8. ME Dudley, JC Yang, R Sherry, MS Hughes, R Royal, U Kammula, PF Robbins, J Huang, DE Citrin, SF Leitman, J Wunderlich, NP Restifo, A Thomasian, SG Downey, FO Smith, J Klapper, K Morton, C Laurencot, DE White, SA Rosenberg: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 26:5233-239 (2008)
9. JJ Hong, SA Rosenberg, ME Dudley, JC Yang, DE White, JA Butman, RM Sherry: Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res, 16:4892-4898 (2010)
10. BJ Coventry, ML Ashdown, MA Quinn, SN Markovic, SL Yatomi-Clarke, AP Robinson: CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med,7:102 (2009)
11. WE Biddison, JC Palmer: Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci U S A, 74:329-333(1977) (Pubitemid 8025847)
12. E Celis, AH Hale, JH Russell, HN Eisen.: Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. I. Changes in reactivity with cytotoxic T lymphocytes and anti-H-2d sera. J Immunol, 122:954-958 (1979) (Pubitemid 9146025)
13. RJ North, I Bursuker: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med, 159:1295-1311 (1984) (Pubitemid 14106450)
14. T Hiura, H Kagamu, S Miura, A Ishida, H Tanaka, J Tanaka, F Gejyo, H Yoshizawa: Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol, 175:5058-5066 (2005) (Pubitemid 41456389)
15. MP Colombo, S Piconese: Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer, 7:880-887 (2007) (Pubitemid 350006256)
16. MW Beilharz, LM Sammels, A Paun, K Shaw, P van Eeden, MW Watson, ML Ashdown: Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression. J Immunol, 172:4917-4925 (2004) (Pubitemid 38456416)
17. AB Heimberger, W Sun, SF Hussain, M Dey, L Crutcher, K Aldape, M Gilbert, SJ Hassenbusch, R Sawaya, B Schmittling, GE Archer, DA Mitchell, DD Bigner, JH Sampson: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol, 10:98-103 (2008) (Pubitemid 351250906)
18. RJ North, M Awwad: Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases noncycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology, 71:90-95 (1990) (Pubitemid 20296077)
19. MR Ehrenstein, JG Evans, A Singh, S Moore, G Warnes, DA Isenberg, C Mauri: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med, 200:277-285 (2004) (Pubitemid 39031247)
20. N Tietz, C Burtis, E Ashwood: Tietz Textbook of Clinical Chemistry. 3rd edition. WB Saunders Company; Philadelphia (1999)
21. H Motulsky, A Christopoulos: Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. Oxford University Press, (2004)
22. S Dimitrov, C Benedict, D Heutling, J Westermann, J Born, T Lange: Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood, 113:5134-5143 (2009)
23. E Haus, DJ Lakatua, J Swoyer, L Sackett-Lundeen: Chronobiology in hematology and immunology. Am J Anat, 168:467-517 (1983) (Pubitemid 14216770)
24. MS Bray, ME Young: The role of cell-specific circadian clocks in metabolism and disease. Obes Rev, 10 Suppl 2:6-13 (2009)
25. O Castanon-Cervantes, M Wu, JC Ehlen, K Paul, KL Gamble, RL Johnson, RC Besing, M Menaker, AT Gewirtz, AJ Davidson : Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol, 185:5796-5805 (2010)
26. A Goldbeter: Computational approaches to cellular rhythms. Nature, 420:238-45 (2002) (Pubitemid 35340136)
27. S Lee, J Kim, B Jang, S Hur, U Jung, K Kil, B Na, M Lee, Y Choi, A Fukui, A Gilman-Sachs, JY Kwak-Kim: Fluctuation of peripheral blood T, B, and NK cells during a menstrual cycle of normal healthy women. J Immunol, 185:756-762 (2010)
28. T Abo, T Kawate, K Itoh, K Kumagai: Studies on the bioperiodicity of the immune response. I. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. J Immunol, 126:1360-1363 (1981) (Pubitemid 11149225)
29. WJ Hrushesky: Circadian timing of cancer chemotherapy. Science, 228:73-75 (1985) (Pubitemid 15122991)
30. WJ Hrushesky, GA Bjarnason: Circadian cancer therapy. J Clin Oncol, 11:1403-1417 (1993) (Pubitemid 23199147)
31. TJ Price, PJ Ross, T Hickish, D Tait, AR Norman, HE Ford, G Middleton, K Sumpter, M Hill, J Oates, D Cunningham: Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer, 3:235-242 (2004) (Pubitemid 38444310)
32. S Giacchetti, B Perpoint, R Zidani, N Le Bail, R Faggiuolo, C Focan, P Chollet, JF Llory, Y Letourneau, B Coudert, F Bertheaut-Cvitkovic, D Larregain-Fournier, A Le Rol, S Walter, R Adam, JL Misset, F Levi: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 18:136-147 (2000) (Pubitemid 30036347)
33. J Hartweg, M Gunter, R Perera, A Farmer, C Cull, C Schalkwijk, A Kok, H Twaalfhoven, R Holman, A Neil: Stability of soluble adhesion molecules, selectins, and Creactive protein at various temperatures: implications for epidemiological and large-scale clinical studies. Clin Chem, 53:1858-1860 (2007) (Pubitemid 47509682)
34. JL Clarke, JL Anderson, JF Carlquist, RF Roberts, BD Horne, TL Bair, MJ Kolek, CP Mower, AM Crane, WL Roberts, JB Muhlestein: Comparison of differing Creactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol, 95:155-158 (2005) (Pubitemid 40051137)
35. AR Rudnicka, A Rumley, GD Lowe, DP Strachan: Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation, 115:996-1003 (2007) (Pubitemid 46328293)
36. M French, ML Ashdown: Intensive monitoring of viral load and C-reactive protein in HIV patients who have chosen to cease highly active anti-retroviral therapy (HAART) Unpublished data from ongoing study, Ongoing study (2003)
37. MR Middleton, JJ Grob, N Aaronson, G Fierlbeck, W Tilgen, S Seiter, M Gore, S Aamdal, J Cebon, A Coates, B Dreno, M Henz, D Schadendorf, A Kapp, J Weiss, U Fraass, P Statkevich, M Muller, N Thatcher: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol, 18:158-166 (2000) (Pubitemid 30036349)
38. ES Schernhammer, F Laden, FE Speizer, WC Willett, DJ Hunter, I Kawachi, GA Colditz: Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst, 93:1563-1568 (2001) (Pubitemid 32998486)
39. J Hansen: Increased breast cancer risk among women who work predominantly at night. Epidemiology 12:74-77 (2001) (Pubitemid 32006465)
40. LG Keith, JJ Oleszczuk, M Laguens: Circadian rhythm chaos: a new breast cancer marker. Int J Fertil Womens Med, 46:238-247 (2001)
41. MC Mormont, AM Langouet, B Claustrat, A Bogdan, S Marion, J Waterhouse, Y Touitou, F Levi: Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int, 19:141-155 (2002) (Pubitemid 34310824)
42. C Banissi, F Ghiringhelli, L Chen, AF Carpentier: Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother, 58:1627-1634 (2009)
43. E Alvino, R Pepponi, E Pagani, PM Lacal, C Nunziata, E Bonmassar, S D'Atri: O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. J Pharmacol Exp Ther, 291:1292-1300 (1999)